Piezo1 channel‐mediated Ca2+ signaling inhibits lipopolysaccharide‐induced activation of the NF‐κB inflammatory signaling pathway and generation of TNF‐α and IL‐6 in microglial cells

Abstract Microglial cells are crucial in maintaining central nervous system (CNS) homeostasis and mediating CNS disease pathogenesis. Increasing evidence supports that alterations in the mechanical properties of CNS microenvironments influence glial cell phenotypes, but the mechanisms regulating microglial cell function remain elusive. Here, we examined the mechanosensitive Piezo1 channel in microglial cells, particularly, how Piezo1 channel activation regulates pro‐inflammatory activation and production of pro‐inflammatory cytokines, using BV2 and primary microglial cells. Piezo1 expression in microglial cells was detected both at mRNA and protein levels. Application of Piezo1 channel activator Yoda1 induced Ca 2+ flux to increase intracellular Ca 2+ concentration that was reduced by treatment with ruthenium red, a Piezo1 inhibitor, or Piezo1‐specific siRNA, supporting that Piezo1 functions as a cell surface Ca 2+ ‐permeable channel. Priming with lipopolysaccharide (LPS) induced microglial cell activation and production of TNF‐α and IL‐6, which were inhibited by treatment with Yoda1. Furthermore, LPS priming induced the activation of ERK, p38 MAPKs, and NF‐κB. LPS‐induced activation of NF‐κB, but not ERK and p38, was inhibited by treatment with Yoda1. Yoda1‐induced inhibition was blunted by siRNA‐mediated depletion of Piezo1 expression and, furthermore, treatment with BAPTA‐AM to prevent intracellular Ca 2+ increase. Collectively, our results support that Piezo1 channel activation downregulates the pro‐inflammatory function of microglial cells, especially production of TNF‐α and IL‐6, by initiating intracellular Ca 2+ signaling to inhibit the NF‐κB inflammatory signaling pathway. These findings reveal Piezo1 channel activation as a previously unrecognized mechanism regulating microglial cell function, raising an interesting perspective on targeting this molecular mechanism to alleviate neuroinflammation and associated CNS pathologies.